Erbitux and Avastin Aren’t Cost Effective, NICE Finds

Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet